FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
Publishing timestamp: 2024-12-19 14:51:46
Summary
FDA announces that the shortage of the active ingredient in Eli Lilly's weight loss drug Zepbound is resolved, which will eventually prevent compounding pharmacies from making unbranded versions. Compounding pharmacies have a 60 to 90-day transition period to switch to the branded version. This decision is part of a high-stakes dispute between compounding pharmacies and the FDA over the shortage of the active ingredient in Zepbound and diabetes treatment Mounjaro.
Sentiment: MIXED
Tickers: LLY,
Keywords: pharmaceuticals, social issues, biotechnology, biotech and pharmaceuticals, health care industry, breaking news: business, business, lilly drn, united states, breaking news, business news,
Source: https://www.cnbc.com/2024/12/19/fda-eli-lilly-weight-loss-drug-zepbound-no-longer-in-shortage.html